ABOS Acumen Pharmaceuticals, Inc.

NASDAQ
$2.24

Acumen Pharmaceuticals, Inc. (ABOS) is expected to report earnings on November 16, 2026, before the market open. The consensus earnings estimate is a loss of $0.43 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -7.1% since its last earnings release on August 12, 2026.

Acumen Pharmaceuticals Missed Consensus Estimates
Wednesday, August 12, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 16
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($0.43)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.84

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Acumen Pharmaceuticals, Inc.

Acumen is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer’s disease.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.